This latest study shows there is no increased risk of heart attack, stroke or death. It also showed Avandia may even be associated with a slightly lower risk of heart attack, stroke or death in certain settings.
The findings were presented by Washington State University researchers at the American Diabetes Association annual meeting.
Two other major studies Monday had the exact opposite results.
No doubt they will all be debated in July when the FDA advisory panel is expected to recommend whether Avandia should stay on the market.
The drug has already weathered years of controversy.
This latest study was funded by the NIH, as well as the maker of Avandia, GlaxoSmithKline.
